Previous Close | 126.84 |
Open | 127.02 |
Bid | 127.00 x 1300 |
Ask | 127.25 x 900 |
Day's Range | 126.32 - 127.56 |
52 Week Range | 104.29 - 138.74 |
Volume | |
Avg. Volume | 1,578,485 |
Net Assets | 7.93B |
NAV | 127.08 |
PE Ratio (TTM) | 16.58 |
Yield | 0.27% |
YTD Daily Total Return | -3.15% |
Beta (5Y Monthly) | 0.75 |
Expense Ratio (net) | 0.44% |
Inception Date | 2001-02-05 |
Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance. No matter what’s going on in the economy, scientists will continue pressing forward for medical innovations. Given the practically limitless opportunities available, this sector enjoys massive pertinence. However, it’s also a volatile arena if you’re choosing individual stocks. While one company ca
Rising interest rates taking steam from rally that powered in IBB and XBI.
The debut highlights the lack of funds focused on the area.
IBB has fallen less than the S&P 500 this year, and may beat again in 2023.
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will be added to the NASDAQ Biotechnology Index® (NASDAQ: NBI), effective December 19, 2022. The NASDAQ Biotechnology Index is designed to track the performance of a set of biotechnology and pharmaceutical companies listed on T
These are seven of the best stocks to buy that can see substantial returns in the months ahead. Despite the ongoing worries on Wall Street, seasoned investors realize that there may be a bull market in some segments of the market even during these gloomy weeks. Fears of sticky inflation and recession led to many investors reevaluating their investments or pulling their money out of the stock markets altogether. As a result, the S&P 500 index has dropped 23% year to date, while the tech-heavy NAS
I’ve written before about how biotech is the biggest technology trend of our kids’ generation. Naturally, that means many people are looking for the best biotech stocks to buy. But as with the PC industry of my time, finding long-term winners is difficult. Back in the early 1980s, dozens of companies entered the PC market, many of them huge for their time. IBM (NYSE:IBM) was the bet everyone made. But the BUNCH — Burroughs, Univac, NCR (NYSE:NCR), Control Data and Honeywell (NASDAQ:HON), were al
Yahoo Finance's Jared Blikre looks at how markets closed on Thursday, with meme stocks and financials leading the way.
Yahoo Finance’s Jared Blikre breaks down how markets opened on Thursday.
Today's reaction to a high CPI print is the opposite of what we saw last month.
Yahoo Finance's Jared Blikre breaks down how markets opened on Wednesday.
Biotech stocks have been brought low over the past 18 months. Both the iShares Biotechnology ETF (NASDAQ:IBB) and S&P Biotech ETF (NYSEARCA:XBI), Wall Street’s two most popular funds that track the industry, dropped 33% and 57% since peaking last February. But the losses were worse two weeks ago. Many biotechs rallied back, and both ETFs are sporting double bottom formations. Unfortunately, some components still have broken trends and remain vulnerable to further downside. I scoured the top hold
Yahoo Finance’s Jared Blikre breaks down how markets opened on Tuesday.
Yahoo Finance's Jared Blikre breaks down today's market action, highlighting some of the best-performing sectors.
Yahoo Finance’s Jared Blikre breaks down how markets opened on Friday.
Yahoo Finance's Jared Blikre joins the Live show to break down how stocks are trading as Fed Chair Powell continues to testify before Congress.
Yahoo Finance's Jared Blikre looks at today's outperformers in the stock market.